Alliance to feature research data for linagliptin and the investigational compound empagliflozin*
INGELHEIM, Germany and INDIANAPOLIS - Tuesday, June 11th 2013 [ME NewsWire]
(BUSINESS WIRE)-- Ex US & UK Medical Media Only
Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the companies’ diabetes alliance will have a strong scientific and clinical presence at the 73rd American Diabetes Association (ADA) Scientific Sessions® in Chicago, 21–25 June, with 34 posters, abstracts and an oral presentation.
Empagliflozin* Data
A total of 17 clinical and pre-clinical abstracts for the investigational agent empagliflozin will be presented, including three late-breaker abstracts. Empagliflozin is a member of the sodium glucose cotransporter 2 (SGLT2) inhibitor class of drugs and is being investigated for the reduction of blood glucose levels in adults with Type 2 Diabetes (T2D). The emerging SGLT2 inhibitor class removes excess glucose through the urine by reducing glucose reabsorption in the kidney.
Details of clinical empagliflozin presentations and published abstracts are as follows:1
Saturday, 22 June, 11:30–13:30, General Poster Session
Sodium Glucose Cotransport-2 Inhibition with Empagliflozin Attenuates Renal Hyperfiltration in Patients with Type 1 Diabetes (T1DM) (Presenting Author: D. Cherney) [Poster No. 1196-P]
Sunday, 23 June, 12:00-14:00, General Poster Session
Empagliflozin Improves Glycemic Parameters and Cardiovascular Risk Factors in Patients with Type 2 Diabetes (T2DM): Pooled Data from Four Pivotal Phase III Trials (Presenting Author: T. Hach) [Late-breaking poster - Poster No. 69-LB]
Metabolic Response to Sodium-Glucose Transporter 2 (SGLT2) Inhibition with Empagliflozin in Patients with Type 2 Diabetes (T2D) (Presenting Author: E. Ferrannini) [Late-breaking poster - Poster No.71-LB]
Empagliflozin (EMPA) Increases Genital Infections but Not Urinary Tract Infections (UTIs) in Pooled Data from Four Pivotal Phase III Trials (Presenting Author: G. Kim [Late-breaking poster - Poster No. 74-LB]
The Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitor Empagliflozin Improves Glycaemic Control in Patients with Type 1 Diabetes: A Single-Arm Clinical Trial (Presenting Author: B. Perkins) [Poster No. 1074-P]
Empagliflozin as Add-On to Metformin Plus Sulfonylurea (SU) for 24 weeks Improves Glycaemic Control in Patients with Type 2 Diabetes (T2DM) (Presenting Author: H. Häring) [Poster No. 1082-P]
Empagliflozin Monotherapy Improves Glucose Control in Drug-Naïve Patients with Type 2 Diabetes (T2DM) (Presenting Author: M. Roden) [Poster No. 1085-P]
Empagliflozin as Add-On to Metformin for 24 weeks Improves Glycaemic Control in patients with Type 2 Diabetes (T2DM) (Presenting Author: L. Merker) [Poster No. 1092-P]
Empagliflozin as Add-On to Basal Insulin for 78 weeks Improves Glycaemic Control with Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM) (Presenting Author: J. Rosenstock) [Poster No. 1102-P]
Empagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) and Renal Impairment (RI) (Presenting Author: H. Rattunde) [Poster No. 1104-P]
Empagliflozin as Add-On to Pioglitazone With or Without Metformin Improves Glycaemic Control in Patients with Type 2 Diabetes (T2DM) (Presenting Author: C. Kovacs) [Poster No. 1120-P]
Empagliflozin Monotherapy for 12 weeks Improves Glycaemic Control in Japanese Patients with Type 2 Diabetes (T2DM) (Presenting Author: M. Haneda) [Poster No. 1144-P]
Design of the Empagliflozin Cardiovascular (CV) Outcome Event Trial in Type 2 Diabetes (T2D) (Author: B. Zinman) [Abstract No. 2349-PO]
Publication Only
Linagliptin Data
A total of 17 clinical and pre-clinical abstracts regarding linagliptin will also be presented, including two late-breaker abstracts. Linagliptin is an inhibitor of the enzyme DPP-4 which breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) that are involved with regulating blood sugar.2
Details of all clinical presentations and published abstracts are as follows:1
Tuesday, 25 June, 8.00–10.00, Oral Presentation – New Information on DPP-4 Inhibition
CV safety of linagliptin in patients with Type 2 Diabetes: a pooled comprehensive analysis of prospectively adjudicated CV events in Phase III studies (Presenting Author: O.E. Johansen) [Oral No: 376-OR] (Pooled data)
Sunday, 23 June, 12.00–14.00, General Poster Session
Lower risk of hypoglycemia in elderly type 2 diabetes patients when linagliptin is added to basal insulin: an exploratory analysis (Presenting Author: M. Von Eynatten [Late-breaking poster – Poster No. 2-LB]
Regardless of the degree of glycemic control, linagliptin (LINA) has Lower hypoglycemia risk than all doses of glimepiride (GLIM) at all time points over a 2-year trial (Presenting Author: B. Gallwitz) [Late-breaking poster – Poster No. 68-LB]
Linagliptin vs. placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment (Presenting Author: S. Patel) [Poster No. 1090-P]
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone (Presenting Author: M. Bajaj) [Poster No. 1093-P]
The dipeptidyl peptidase (DPP)-4 inhibitor linagliptin improves beta cell function and postprandial glucose in patients with type 2 diabetes (Presenting Author: M. Larbig) [Poster No. 1138-P]
Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: a 24-week, randomised, Phase III clinical trial (Presenting Author: Y. Chen) [Poster No. 1159-P]
Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin: a 24-week, randomised, Phase III clinical trial (Presenting Author: W. Wang) [Poster No. 1177-P]
Baseline characteristics of patients enrolled in the cardiovascular outcome study of linagliptin versus glimepiride in patients with Type 2 Diabetes (CAROLINA) (Published Author: N. Marx) [Abstract book for the American Diabetes Association (ADA) 73rd Scientific Sessions]
Publication Only
Linagliptin, which is marketed as Trajenta® 5mg tablets in Europe, is a once-daily tablet used along with diet and exercise to improve glycaemic control in adults with Type 2 Diabetes. Linagliptin should not be used in patients with Type 1 Diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). Linagliptin is a DPP-4 inhibitor that does not require dose adjustments that may be brought about by declining renal function or hepatic impairment.
~ENDS~
Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/11_june_2013_diabetes.html
Contacts
Dr. Ralph Warsinsky
Corporate Communications
Boehringer Ingelheim GmbH
Email: press@boehringer-ingelheim.com
Phone: +49 178 290 8561
Tammy Hull
Communications Manager
Lilly Diabetes
Email: hullta@lilly.com
Phone: +1 317 651 9116
No comments:
Post a Comment